Nae-Fang Twu1, Yu-Che Ou2, Cheng-I Liao3, Wei-Yang Chang4, Lan-Yan Yang5, Yun-Hsin Tang6, Tze-Chien Chen7, Chi-Hau Chen8, Tze-Ho Chen9, Lain-Shung Yeh10, Shih-Tien Hsu11, Yu-Chieh Chen12, Cheng-Chang Chang13, Ya-Min Cheng14, Chia-Yen Huang15, Fu-Shing Liu16, Yue-Shan Lin17, Sheng-Mou Hsiao18, Yuan-Yee Kan19, Chyong-Huey Lai20. 1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan. 2. Department of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan. 3. Department of Obstetrics and Gynecology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. 4. Biostatistics and Informatics Unit, Clinical Trial Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan. 5. Biostatistics and Informatics Unit, Clinical Trial Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan; Gynecologic Cancer Research Center, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan. 6. Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan; Gynecologic Cancer Research Center, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan. 7. Department of Obstetrics and Gynecology, Mackay Memorial Hospital, Taipei, Taiwan. 8. Department of Obstetrics and Gynecology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan. 9. Department of Obstetrics and Gynecology, Changhua Christian Hospital, Changhua, Taiwan. 10. Department of Obstetrics and Gynecology, China Medical University Hospital, China Medical University College of Medicine, Taichung, Taiwan. 11. Department of Obstetrics and Gynecology, Taichung Veterans General Hospital, Taichung, Taiwan. 12. Department of Obstetrics and Gynecology, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan. 13. Department of Obstetrics and Gynecology, Triservice General Hospital, National Defense University, Taipei, Taiwan. 14. Department of Obstetrics and Gynecology, National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan. 15. Gynecologic Cancer Center, Department of Obstetrics and Gynecology, Cathay General Hospital, Taipei, Taiwan; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan. 16. Department of Obstetrics and Gynecology, Show Chwan Memorial Hospital, Changhua, Taiwan. 17. Department of Obstetrics and Gynecology, Chi-Mei Medical Center, Tainan, Taiwan. 18. Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, Banqiao, New Taipei, Taiwan. 19. Department of Obstetrics and Gynecology, Yuan's General Hospital, Kaohsiung, Taiwan. 20. Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan; Gynecologic Cancer Research Center, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan. Electronic address: sh46erry@ms6.hinet.net.
Abstract
OBJECTIVE: We aimed to identify prognostic factors of early-stage cervical adenocarcinoma (AC) and adenosquamous carcinoma (ASC) treated with primary radical surgery, and to evaluate the impact of postoperative adjuvant therapy on outcome. METHODS: The clinical-pathological data of all patients (n = 1132) with stages I-II cervical AC/ASC treated with primary radical surgery at the member hospitals of the Taiwanese Gynecologic Oncology Group were retrospectively reviewed. RESULTS: In multivariate analysis, stage II, deep stromal invasion (DSI), lymphovascular space invasion (LVSI), positive pelvic lymph node (PLN), and parametrial involvement (PI) were significant factors for recurrence-free survival (RFS), while only DSI, PI, and positive PLN were independent factors for cancer-specific survival (CSS). Low- and high-risk groups were defined by prognostic scores derived from the four factors (DSI, LVSI, positive PLN, PI) selected by internal validation. Postoperative adjuvant therapy significantly improved outcome for PLN-positive patients (RFS, p = 0.014; CSS, p = 0.016), but not for PLN-negative high-risk group because of higher mean prognostic score (p = 0.028) of adjuvant+ than adjuvant- patients. CONCLUSIONS: PLN metastasis, PI, DSI, and LVSI were independent prognostic factors. Prospective studies of postoperative adjuvant therapy with prognostic score and nodal status stratification for cervical AC/ASC are necessary.
OBJECTIVE: We aimed to identify prognostic factors of early-stage cervical adenocarcinoma (AC) and adenosquamous carcinoma (ASC) treated with primary radical surgery, and to evaluate the impact of postoperative adjuvant therapy on outcome. METHODS: The clinical-pathological data of all patients (n = 1132) with stages I-II cervical AC/ASC treated with primary radical surgery at the member hospitals of the Taiwanese Gynecologic Oncology Group were retrospectively reviewed. RESULTS: In multivariate analysis, stage II, deep stromal invasion (DSI), lymphovascular space invasion (LVSI), positive pelvic lymph node (PLN), and parametrial involvement (PI) were significant factors for recurrence-free survival (RFS), while only DSI, PI, and positive PLN were independent factors for cancer-specific survival (CSS). Low- and high-risk groups were defined by prognostic scores derived from the four factors (DSI, LVSI, positive PLN, PI) selected by internal validation. Postoperative adjuvant therapy significantly improved outcome for PLN-positive patients (RFS, p = 0.014; CSS, p = 0.016), but not for PLN-negative high-risk group because of higher mean prognostic score (p = 0.028) of adjuvant+ than adjuvant- patients. CONCLUSIONS: PLN metastasis, PI, DSI, and LVSI were independent prognostic factors. Prospective studies of postoperative adjuvant therapy with prognostic score and nodal status stratification for cervical AC/ASC are necessary.
Authors: Xiao-Li Chen; Guang-Wen Chen; Guo-Hui Xu; Jing Ren; Zhen-Lin Li; Hong Pu; Hang Li Journal: Int J Gynecol Cancer Date: 2018-10 Impact factor: 3.437
Authors: Huihui Zhou; Qi Li; Chunyan Xu; Hong Liang; Yanan Wang; Yani Duan; Min Song; Yaoxian Wang; Hong Jin; Tong Wang Journal: Transl Cancer Res Date: 2020-04 Impact factor: 1.241